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CHAPTER I 
INTRODUCTION 
1.1 The Mental Health Burden 
Neurotransmitters such as serotonin and norepinephrine are important in 
regulating almost all aspects of human behavior. Incorrect regulation of these 
neurotransmitters can lead to a variety of mental disorders, many of which are 
significantly detrimental to the person's general functioning and quality of life. The most 
common of these include depression, anxiety, autism, and ADHD. According to the 
NIMH in 2005, there was a lifetime prevalence of 20.8% of the US population that will 
suffer from a mood disorder, 28.8% that will suffer from an anxiety disorder, 8.1% that 
will suffer from ADHD, and 1 in 110 children born suffer from some form of autism. In 
2006, the NIMH estimated that $57.5 billion was spent by both the healthcare system and 
individuals on the treatment of mental illness, with 36% of the population seeking 
treatment. According to their statistics, only 50% or less of the people suffering from the 
disorders specified received pharmaceutical treatment1. It is clear that these disorders are 
significant burden on the overall and financial wellbeing of our society.  
Research on these neurotransmitters has become increasingly prevalent since 
advent of antidepressant and antianxiety medications, but it is still unknown how exactly 
this problem with regulation is connected to disease. The diagnosis of these diseases is 
mainly done through interview and questionnaires developed through years of psychiatric 
theory. A patient will typically be suffering from their symptoms for months or even 
years before being considered for treatment. Pharmaceutical treatment is determined 
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largely by trial and error, sometimes taking months for a patient to find the correct 
medication and dosage to bring them relief. This process is extremely time consuming, 
and the cost to both individuals and the health care system increases every year. Studying 
the behavior of the transporter proteins of these nuerotransmitters on the single molecule 
level can help to understand the mechanism of disease, develop better pharmaceuticals, 
and make diagnosis and treatment more accurate and individualized.   
 
1.2  Serotonin and Norepinephrine     
The body uses serotonin to regulate learning, mood, memory, sexuality and sleep 
among other functions. Serotonin transporter protein (SERT) is a 12 domain, 
transmembrane protein responsible for the clearance of excess serotonin from the synapse 
after it is released. Serotonin is taken back into the neuron and stored in vesicles until it is 
released again2. SERT malfunction has been linked to many psychological disorders 
including depression, autism, anxiety and obsessive compulsive disorder3. Depression 
alone is one of the leading causes of disability in the world (WHO)4, and autism is the 
fastest growing cause of learning disability in the US (TACA)4, 5. Several mutations for 
SERT have been associated with certain of these diseases, and several cellular 
components have been shown to affect SERT activity and trafficking3.  
Norepinephrine and its transporter work very similarly to serotonin and SERT. 
NET protein is almost identical in structure, and not only transports norepinephrine but 
also dopamine and epinephrine. These all have similar effects as serotonin, but they are 
also responsible for activating the attention centers of the brain, cognitive ability and 
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movement. Norepinephrine and epinephrine control the body’s “fight or flight” response, 
and figure heavily in the body’s response to pain and pleasure6.  Since it transports 
several monoamines, malfunction of the norepinephrine transporter contributes to 
disorders caused by disregulation of dopamine and norepinephrine. These also include 
depression, learning disorders, ADHD, schizophrenia, and hypotension7. The function of 
NET and SERT effect the regulation of many monoamines, not just serotonin and 
norepinephrine, and understanding both along with dopamine transporter is crucial in 
developing a picture of the whole system. 
 
Figure 1.1: Norepinephrine and serotonin in the synapse8 
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Figure 1.2: SERT protein model9 
 
1.3 Targeting SERT and NET 
 As has already been mentioned, the transporter proteins convey several different 
monoamines, but they can also bind drugs and other small molecules. This has been a key 
point in the approach used in the Rosenthal group to study these proteins. Amphetamines, 
cocaine, some hallucinogenic drugs, and antidepressants all bind to and have various 
activating or inhibiting effects on these transporter proteins and have all been considered 
as models for small molecule targets for the ligands used in these experiments. Ian 
Tomlinson has developed several targeting ligands for monoamine transporters, two of 
which are currently used to label SERT in cells, IDT318 and IDT361. They both use a 
high affinity serotonin derivative to target SERT. This small molecule is attached to a 
PEG5000 chain by an 11 carbon alkyl spacer. The alkyl spacer provides enough distance 
between the membrane and hydrophilic PEG chain to allow the target to bind to the 
SERT. Biotin is bound to the other end of the PEG chain to complete the ligand. The IC50 
of IDT318 is 3.4uM and the IC50 of 361 is 0.034uM
10. 
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 C 
Figure 1.3: (A) IDT318 complete with (left to right) biotin attached to PEG5000 attached 
to the alkyl spacer with the targeting ligand. (B) IDT361 (C) Serotonin (5
There are several NET targeting ligands Tomlinson has 
although thorough testing has not yet been performed. 
IDT 588 is a tropane derivative, and IDT 545 and 488 are atomoxetine derivatives
Figure 1.4). All of them can serve as norepinephrine reuptake inhibitors. Screening is 
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Hydroxytrytophan) 
 
synthesized as well, 
IDT 465 is a talopram derivative, 
 
 
-
 (See 
 done by first incubating with varying concentrations of the ligand for 30 minutes, then 
incubating with 10uM IDT307
cells can be quantitatively compared to establish the degree of uptake for each 
concentration of the ligand. After an initial range of effective concentrations is 
established, they can be tested for labeling. 
1.4 Semiconductor Nanocrystals
 Semiconductor nanocry
biological setting have been used since 1998
for a number of reasons. Their small size (4
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 and imaging. The fluorescence intensity of individual 
 
Figure 1.4 
 
 
stals or quantum dots (QDs) developed for use in a 
11. QDs are ideal for biological application 
-20nm) makes them easy to use in biologi
 
 
cal 
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and cellular systems. Due to quantum confinement, they have a small, size dependent 
fluorescent emission. Being inorganic in composition, they are far less susceptible to 
photodegradation than organic fluorophores, allowing them to be viewed for much longer 
periods of time. They have a large molar extinction coefficient and high quantum yields, 
which gives them an intense fluorescent signal. All of these properties allow for even a 
single quantum dot to be a powerful tool for observation. QDs also have the unique 
property of fluorescence intermittency or blinking that allow the observer to ascertain that 
a single quantum dot is providing the signal, as opposed to an aggregate of dots. This 
property is especially important in the case of single molecule tracking12.  
 Other methods used to study SERT behavior suffer from poor spatial resolution, 
difficult preparation, high cost, or low photostability. Organic fluorophores are easily 
obtained, but they photobleach in a matter of seconds. Radiolabled ligands are expensive, 
require special handling, and also have poor spatial resolution. Antibodies are highly 
specific in most cases, but they are bulky, expensive, difficult to prepare, and do not 
target SERT well. Patch clamp measurements give information on the activity of SERT, 
but do not give positional information13. 
 The quantum dots used for these experiments are purchased from Invitrogen. 
Their peak emission wavelength is 655nm (See Figure 1.5). They are composed of a 
Cd/Se core with a Zn/S shell. Since the passivating surface ligands present after synthesis 
are nonpolar and therefore insoluble in water, an ampiphilic polymer interacts with the 
non polar surface ligands and is crosslinked with itself . The polymer has reactive groups 
on the outer surface allowing for easy conjugation of targeting moieties (See Figure 1.6). 
This allows proteins, DNA, peptides, antibodies, and small molecules to be attached to 
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the surface of the QD. The QDs used are carboxylic acid terminated to allow streptavidin, 
a protein with high affinity binding to biotin, to be conjugated to the surface. This strong 
interaction is utilized to bind the quantum dot to a targeting ligand12. 
 
 
Figure 1.5: Absorption and emission spectrum of QD655 from Invitrogen 
 
 
Figure 1.6: Diagram of Quantum Dot. (A) Organic passivating ligands (B) Ampiphilic 
polymer (C) Carboxylic Acid groups12 
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1.5 The Development of our Labeling Process 
The specificity of IDT318 has been well characterized by previous experiments 
performed by Michael Warnement and Jerry Chang. The ligand was originally tested in 
an oocyte model. Oocytes are large, easily imaged, and have extremely high expression 
levels of the protein it is transfected with.  Oocytes were injected with a cRNA vector and 
incubated for several days before testing. The IC50 value was determined by incubating 
the oocyte with IDT318 and tritiated serotonin. The concentration of IDT318 was 
gradually increased, and the concentration was plotted against the accumulated 
radioactivity. Patch clamp methods were used confirm inhibition of SERT activity by 
measuring the difference in the influx voltage when the oocyte was treated with 318 and 
serotonin and just with serotonin. The current was 80% lower when treated with 318, 
even after the excess 318 was removed from solution, indicating that the ligand remained 
bound. Imaging using confocal microscopy was used to determine if the SERTs could be 
labeled successfully. The oocytes were first incubated with the ligand for an hour, and 
then incubated with the streptavidin conjugated quantum dots separately for 5 minutes. 
Nonexpressing oocytes were treated with the quantum dots to determine the degree of 
nonspecific binding to the oocyte membrane. The SERT transfected oocytes were also 
imaged with just the quantum dots to determine the degree of nonspecific binding with 
SERT. SERT transfected oocytes blocked with paroxetine, a high affinity antidepressant 
that targets SERT, were treated with 318 and the quantum dots to establish that SERT 
was successfully expressed and labeled. Though all of them show some labeling, the 
labeling in the SERT transfected oocytes treated with 318 and QD655 is significantly 
greater than in the controls14.  
10 
 
 
 
Figure 1.7: Bright field and fluorescent images of the oocytes (A-B) SERT transfected 
oocyte treated with IDT318 and Streptavidin QD’s, (C-D) SERT transfected with just 
QD’s, (E-F) Non-expressing oocyte treated with IDT318 and QD’s, and (G-H) SERT 
transfected and treated with paroxetine prior to IDT318 and QD’s14 
 
IDT318 was further studied in Hek-293T cells, as they can be easily transiently 
transfected and lifted from the culture vessel for imaging in suspension. The cells were 
transfected using a pc3DNA vector and Lipofectamine-2000, a transfection reagent 
purchased from Invitrogen. A “sham” pc3DNA vector was used as a control to account 
for effects from the transfection process. IDT307, a small molecule developed in the 
Rosenthal lab that fluoresces when taken up by monoamine transporters, was used to 
quickly and easily determine the success of the transfection. The paroxetine block was 
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also used to establish the expression of SERT since IDT307 can be taken up by several 
different transporters. The same two step labeling process was used to label SERT in 
Hek293T cells. The cells were incubated with the ligand, and trypsin was used to detach 
the cells from the plate before centrifugation and incubation with the quantum dots. 
SERT specific labeling was observed. Flow cytometry was used to confirm that a SERT 
labeled population existed that was significantly higher than in sham transfected cells, 
paroxetine blocked SERT transfected cells, and SERT transfected cells only incubated 
with the quantum dots. Flow cytometry was also used to determine an optimal incubation 
time and 318 concentration, ideal alkyl spacer length on the ligand, and specificity of the 
ligand for SERT over dopamine transporter15. The IC50 value of IDT361 was determined 
by patch clamp methods, but information on the the specificty and labeling ability has not 
been published.   
     
Figure 1.8: IC50 value of IDT318 determined by serotonin uptake and leak14 
current 
 
 The purpose of the experiments performed as part of this project was to establish 
labeling ability of new ligands to target SERT and NET. IDT361 and IDT545 were both 
tested in Hek293T cells. Since flow cytometery experiments have already been 
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performed to establish the specificity of IDT361 to SERT, the next step was to show 
labeling in live cells. Since NET has not been studied in the Rosenthal lab much thus far, 
the successful amplification of the plasmid and optimum transfection conditions needed 
to be established before experiments on cells could be done. Then, the initial experiments 
to show specificity and activity were performed.    
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CHAPTER II 
EXPERIMENTAL 
2.1 Cell Maintenance  
Cells were maintained according the recommendations of the ATCC. All cells are 
maintained in a sterile 5% carbon dioxide environment at 32°C. Standard aseptic 
techniques were followed for all cell maintenance protocols. All cells were obtained as a 
gift from the Dr. Randy Blakely lab (Vanderbilt University).   Hek-293T cells were 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 4.5 g/L 
glucose, 1.0 mM sodium pyruvate and 2 mM L-glutamine with 10% fetal bovine serum 
and 100ug/mL penicillin and streptomycin.  HeLa cells were also maintained in the same 
way. Cells were passaged after reaching 90% or more confluence.  Once the cells reached 
the desired confluence, the media was removed and a trypsin/EDTA solution (Gibco) was 
added to induce cell detachment at 37 °C. After the cells detach from the flask, a three 
fold excess of complete media was then added to neutralize trypsin activity, and the cells 
were aliquoted to a new flask with an appropriate volume of complete media. 
 
2.2 Plasmid Preparation and Cell Transfection 
Transfection was used to induce SERT and NET production in Hek-293T cells 
and HeLa cells. The plasmid DNA encoding for SERT in a pcDNA3.1 vector was 
originally obtained as a gift from the Blakely lab. Competent DH5α E. coli cells 
incubated with 1 µL of plasmid DNA, and then heated at 42°C for 30 seconds to induce 
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the bacteria to take up exogenous plasmid. These heat shocked cultures were 
subsequently streaked onto LB-ampicillin agar plates and stored overnight at 37°C. The 
pcDNA3.1 vector has an ampicillin resistance coded into it, so only those E. coli cells 
which have taken up plasmid will be able to survive in the presence of ampicillin. A 
single colony was picked from the plate, and deposited into 125 mL of LB medium 
containing ampicillin. These cultures were then incubated overnight at 37°C with 
vigorous shaking. Afterwards, the plasmid DNA was purified using a plasmid midi kit 
(Qiagen). An alkaline lysis buffer is used to extract plasmid from bacteria and a series of 
buffers, purification columns and centrifugation are used to complete purification. 
Spectroscopic determination of plasmid concentration was then performed using a 
NanoDrop spectrophotometer. The plasmid was stored in Tris-EDTA buffer at 4°C 
before use.  
Transient transfection was used for SERT production in cells because it typically 
causes higher expression levels in cells than in stably transfected cells. Lipofectamine 
2000 (Invitrogen) is used as the transfection agent, and the suggested protocol for this 
reagent from the manufacturer was followed. Cells are incubated with 0.8ug plasmid and 
2uL Lipofectamine for 24 to 48 hours before use. Transfection efficiency was tested by 
use of IDT307, a compound that, when transported by monoamine transporters, 
fluoresces green. Transfections were performed in a 24 well plate format. 0.8 µg plasmid 
DNA and 2 µL Lipofectamine 2000 were added to each well, according to manufacturer 
recommendations. Control cells are transfected with an empty pcDNA3.1 vector termed 
“sham” to eliminate any potential experimental interference resulting from exposure to 
transfection reagents. Transfections were performed at a confluence of ~90% as the 
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Lipofectamine 2000 is cytotoxic, and is detrimental to the cell population below this level 
of confluence.  
 IDT307 was originally developed in the Rosenthal lab. It is a small molecule 
selectively transported by monoamine transporters, and only fluoresces inside the cell. 
IDT307 can be used to assess transporter activity. IDT307 can be added directly to media 
of the cell culture at 10uM concentration incubated at 37°C for five to ten minutes for 
successful imaging. A standard GFP filter set can be used to image uptake of IDT307 
confirming successful transporter expression. The media is removed and replaced with 
room temperature PBS just before imaging to ensure no background fluorescence from 
FBS.  
 
2.3 Transporter Labeling 
Transporter labeling is accomplished using a two step process. The cells are 
cultured in a 24-well plate, and transfected as described. The original media is removed 
to eliminate background from serum proteins that will bind to the quantum dot.  The cells 
are incubated in phenol free media or PBS with the ligand for an hour. The cells detach 
from the plate when the PBS is added. After an hour, the cells are transferred to 
microfuge tubes and a 0.5nM QD655Sav (Invitrogen) solution in PBS is added, and they 
incubated on ice for 5 minutes. The cells are centrifuged for 5 minutes and resuspended 
cold cell stripper (Cellgro). They are centrifuged and respended until the desired number 
of washes have been completed. After the final wash, 50uL of the cell suspension is 
placed on a glass coverslip for imaging. The cells are washed and imaged in suspension 
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because it greatly reduces background from unbound quantum dots, and quantum that 
will adhere to the surface of the culture plate.   
Images were obtained using the Zeiss Axiovert 200 Epifluroescent Microscope. 
The system is located in our lab and is equipped with a mercury vapor lamp as a light 
source. The objectives used for included images are 20x, 40x, and 100x. The microscope 
is used in conjunction with Metamorph image acquisition software. The GFP filter set 
(512nm emission) is used for IDT307 imaging. The QD655 filter set (655nm emission) is 
used to image labeling of SERT. Imaging is done either directly in the culture plate, or 
the cells are suspended in buffer and imaged on a glass slide. Imaging is done at room 
temperature. 
 
2.4 Ligand Screening 
 The cells were grown up in the desired size plate, usually a 24 wells plate. They 
were transfected with the appropriate plasmid for the type of targeting ligand that was 
screened. Screening is done by first incubating with varying concentrations of the ligand 
for 30 minutes, then incubating with 10uM IDT307 and imaging. The fluorescence 
intensity of individual cells can be quantitatively compared to establish the degree of 
uptake for each concentration of the ligand. After an initial range of effective 
concentrations is established, they can be tested for labeling.  
  
 3.1 Transfection Efficiency 
Initial work was done with HeLa
sample and now widely used in research. HeLa cells are robust, fast growing epithelial 
cells that adhere well to p
detaching from the culture surface
good for labeling experiments but display a greater degree of nonspecific binding with 
IDT307, which makes them unattractive for uptake and screening assays.
images taken with HeLa cells of
expression of the SERT protein
background signal, there is a much greater degree of internalization of IDT307 in the 
SERT transfected cell.   
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CHAPTER III 
RESULTS AND DISSCUSSIONS 
 
 cells, a cell line derived from a cervical cancer 
lastic plates and flasks. They are easily washed without 
 and are not easily damaged. For these reasons, they are 
 IDT307 uptake of SERT transfected cells
. It can be seen that even after adjusting for the 
 
Figure 3.1: Scale bar=20µm 
 Below are 
 to confirm the 
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3.2 Ligand Screening 
For screening both SERT and NET ligands, Hek-293T cells, human embryonic 
kidney cells, were used because they are easily transfected and display a lesser degree of 
nonspecific binding. Hek-293Ts do not show as much background with IDT307, but 
detach from the plate readily, so washing must be done with care. Even slight changes in 
temperature can cause them to detach from the plate, so imaging must be done carefully 
and quickly. Attempts to synthesize more IDT318 have been unsuccessful recently, so 
testing for a new SERT targeting ligand began with IDT361. It was seen in previous 
experiments that 361 had an even higher affinity for SERT than IDT318 does. This 
makes it particularly attractive for single molecule tracking studies. Shown in Figure 11 
are HeK293T cells transfected with SERT and a sham plasmid and incubated with 
IDT361 and QD655. As can be seen in the images, the SERT transfected cells are clearly 
labeled with quantum dots, whereas the sham transfected cells do not show any labeling 
above the background.  
 
 
 
 
 
 
 
 (A) 
(B)  
SERT 
 
 
 
 Sham 
 
 
Figure 3.2: Scale bar=20µm
QD 655, (B) SERT and Sham transfected cells treated with 
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, (A) SERT and Sham transfected cells treated with 361 and 
IDT307
 
 
 
 3.3 Ideal Transfection Conditions for NET Expression
Ideal transfection conditions for NET expression were tested according to 
Invitrogen’s protocol. Varying volumes of Lipofectamine 2000 and 0.8ug of plasmid 
DNA were incubated with the cells. 
the transfection. Cells were incubated with 10uM 
imaged. Sham transfected cells were used as a 
uptake of IDT307 increases with increasing
cell damage occurred when more than 4uL was used during transfection. 
Figure 3.3
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IDT307 uptake was used to determine the success of 
IDT307 in PBS for 10 minutes and then 
control. As can be seen in Figure 12, the 
 amounts of Lipofectamine, but significant 
 NET transfection conditions 
 
 
 
 
 3.4 Testing NET Ligand IDT545
 To establish the potential of IDT545 to be used for targeting and 
labeling NET with QD’s, Hek293T cells were grown up in a 24 well plate and transfected 
with NET and sham plasmid. After 24 hours, the cells were incubated with various 
concentrations of IDT545 for 20 minutes.
an effective concentration of less (preferably much less) than 10uM is ideal for labeling. 
The cells were then treated with 10uM IDT307 for 10 minutes. 
removed and replaced with PBS just before imaging. In the images, the ligand 
seem to block the uptake of 
Therefore, it is unlikely that this ligand would be used for further study. 
Figure 3.4
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eventually 
 The concentrations used were chosen 
The cell media was 
IDT307 appreciably at any of the concentrations used. 
 
: IDT545 activity Scale bar=105µm 
because 
does not 
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CHAPTER IV 
CONCLUSIONS AND FUTURE DIRECTIONS 
4.1 Single Molecule Tracking  
 Single molecule tracking with quantum dots began with the Dahan group in 2003. 
Quantum dots were used to label glycine receptors in neurons. Using the mean squared 
displacement and comparing diffusion coefficients of the particles, they were able to 
distinguish two populations of receptors—ones that were freely moving and ones that 
were confined to specific areas16.  In the Rosenthal lab, the statistical analysis has been 
combined with our labeling process to characterize the behavior of SERT and DAT. The 
original tracking data is obtained using a process called FIONA, or fluorescence imaging 
with one nanometer accuracy. It utilizes a point squared function, a two dimensional 
Gaussian curve comparing the fluorescence intensity on the x axis and the intensity on 
the y axis. Because of the diffraction limit, objects observed in light microscopy cannot 
be seen any sharper than 250nm. By using this function, the exact center of the particle 
(the centroid of the PSF) can be determined on the subpixel scale. In confocal 
microscopy using a 63x objective, a pixel is 200nm2, much larger than SERT or a QD. 
The use of the PSF not only allows one to determine the position of the particle at the 
1nm scale, but causes of noise such as pixilation, camera readout, and fluorescent 
background are minimized by collecting more photons from a signal. This makes QDs 
perfect for this type of analysis due to their brightness. PSF measurements are only 
accurate if it is symmetrical. Spherical aberration and defocusing can cause the center to 
change up to 50nm17. Using single quantum dot tracking, SERT behavior can be quickly 
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and easily visualized and followed in real time, providing a fluorescent technique that can 
be used to obtain positional data with high spatial resolution, high, robust signal, and 
specific targeting. 
Jerry Chang has already done an extensive study of the movement and behavior 
of endogenous SERTs in rat neurons, RN46A13. His work has confirmed that SERT is 
localized in cholesterol rich, lipid rafts by using Alexa Fluor 488-conjugated cholera 
toxin subunit B, which binds to ganglioside GM1 which has been shown to be in these 
lipid rafts.14 The cells showed co-localizion of the CTxB and the QD labeled SERTs. 
This association was further explored by treating the cells with methyl-ß-cyclodextrin, a 
cholesterol chelator. After treatment, the CTxB and the SERTs were dispersed. 
Comparing the tracking data, the instantaneous velocity of the SERTs in the MßCD 
treated cells was considerably higher than in the control cells. A plot of the log of the 
mean squared displacement vs. log time indicated that SERTs in the control cells have a 
confined lateral diffusion whereas in the MßCD treated cells, SERTs display free 
diffusion. A histogram of the individual diffusion coefficients indicated a single 
population of SERTs for control cells (as they are all confined), and two populations for 
MßCD treated cells, one large, fast population, and one small, slower population 
consistent with the control cells. Protein kinase G phosphorylates SERT after activation 
by cyclic guanosine monophosphate (cGMP). This has been shown to increase movement 
and serotonin uptake18. 8-bromo-cGMP was used to activate PKG in RN46A cells, and 
the mean instantaneous velocity of the SERTs increased significantly. The distribution of 
the individual diffusion coefficients indicated that there were more SERTs with high 
diffusion compared to the control. The log-log plots indicated that the SERTs still 
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showed confined lateral movement. PKG activation causes mobilization of intracellular 
SERTs to the surface of the cell, which may account for the increase in mobility of 
labeled SERTs13. It has also been shown that p38 mitogen-activated protein kinase 
activation triggered by PKG also causes intracellular SERTs to rise to the surface18. To 
determine whether the increase in SERT trafficking was due to p38 MAPK activation or 
PKG activation alone, the cells were treated with 8-Br-cGMP and a p38 MAPK inhibitor, 
SB203580. This significantly decreased the increase in SERT instantaneous velocity 
from the 8-Br-cGMP treatment. The displacements of the individual SERTs can be better 
visualized by looking at the lateral trajectories over a 5 second period. These plots from 
the control, MßCD, and 8-Br-cGMP treatments were compared. These give a clearer 
picture of the degree of confinement of the SERTs. Control cells showed very little 
lateral displacement, the MßCD treated cells had very dispersed SERTs, and the 8-Br-
cGMP treated cell’s SERTs showed similar displacement to the control cells. RN46A 
cells were treated with an inflammatory cytokine, IL-1ß, to determine the effect of p38 
MAPK activation independent of PGK activation on SERTs. The results were similar to 
those obtained by treating the cells with 8-Br-cGMP. An actin filament disruptor, 
cytochalasin D, was used to disrupt the cytoskeleton of the cells, which could restrict 
movement within nearby lipid rafts. While two populations of SERTs were observed in 
the diffusion rates like with 8-Br-cGMP and IL-1ß treatments, an overall increase in the 
diffusion rate occurred in both populations. The instantaneous velocity of the lipid rafts 
themselves also increased, but the SERTs remained co-localized in the rafts. IL-1ß 
treatment with CytoD did not increase the velocity further, but MßCD treatment with 
CytoD did. This indicates that the IL-1ß activation of the SERTs is a result of the release 
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of the transporter from the cytoskeleton, but not the lipid raft13. It has been shown that 
SERT associates with integrins and integrin associated proteins through its C-terminal 
domain inside the cell. These proteins facilitate interaction between the SERT and the 
cytoskeleton18. To determine whether these interactions could account for restricted 
motion of the SERTs, the cells were treated with TAT-C-terminal SERT peptides. The 
results were similar to IL-1ß treatment, and importantly, the treatment caused an increase 
in SERT activity. This was determined by comparing the uptake of IDT307 in control 
cells and in C-SERT peptide treated cells.  Time lapse images show that uptake of 
IDT318 in C-SERT peptide treated cells is significantly higher, and increases over a 30 
minute period. This indicates that SERT activity is increased when untethered to the 
cytoskeleton despite still being confined to the lipid raft13. 
However, all of these experiments were done with IDT318, which has not 
working for the past year. In the future, studies with the RN46A rat neuron cells used for 
previous SERT studies will be done using IDT361 to establish its transferability. The 
advantage of using neuron cells is that it is a system that endogenously produces SERT 
so it can be studied in one of its most natural environments short of actual in vivo studies. 
However, this system expressed rat SERT, not human SERT, which is not vastly 
different, but still not the same. The screening process described for IDT318 will also 
need to be repeated for IDT361 to confirm it’s appropriateness for these studies. 
Hek293T cells will also be used to study IDT361’s relationship with SERT.  
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4.2 SERT Mutations 
 Our collaborators in the Blakely lab have stably transfected Chinese Hamster 
Ovary cells with a SERT mutant associated with autism, G56A. This mutation, associated 
with increased SERT activity, transmits 3:1 to people with autism (to males 
preferentially) and is also associated with sensory aversion and rigid compulsive traits in 
these cases. This mutation is located near the N terminus of the SERT (See Figure 14). 
This variant of SERT has shown no response to PKG and MAPK activation, which 
usually increases SERT activity. It also increases sensitivity to PKC compared to wild 
type SERT, which increases activity more than it should. It also shows insensitivity to 
Ser/Thr protein phosphatase 2A. When this phosphatase is inhibited, SERT is 
phosphorylated, and its activity is reduced3. Using single molecule tracking of these 
mutated SERTs, the effect of this mutation and these associations could be explained by 
observing the movement of the protein. The activity could be easily observed under these 
and other conditions known to effect SERT activity, which could reveal biomarkers that 
could be used for diagnosis or treatment.  Profiling this mutation and others could also 
lead to the development of gene therapy. 
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Figure 4.1 SERT mutations 3 
 
4.3 Targeting NET and Multiplex Experiments 
 The Rosenthal lab has been studying SERT and DAT for several years now, 
having already found targeting ligands for them. Much of the work done for SERT has 
already been described, and a great deal of information has obtained for both SERT and 
DAT in our group. Without studying NET though, the picture of these monoamine 
transporters is incomplete. There are still several more NET targeting ligands to be 
screened and more are being synthesized. A ligand with an IC50 value of 5uM or lower 
for NET would be ideal for labeling, imaging, and single molecule tracking.  With 
multiple targeting ligands, simultaneous labeling experiments could be done. This would 
allow for the visualization of not only the behavior of the individual transporters but also 
their effect on each other.  
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